王潔

北京大學腫瘤醫院胸部腫瘤內一科(原胸部腫瘤內科)主任醫師、教授、博士生導師，科主任。多年來一直致力於肺癌規範化、個體化、多學科綜合治療及相關研究。2002年12月至2004年12月接受美國NCI“Oncology Research Faculty Development Program”資助，在M.D.Anderson Cancer Center胸部腫瘤內科學習肺癌為主實體瘤臨床治療及相關應用基礎研究，豐富了肺癌個體化多學科綜合治療臨床經驗，對肺癌發生髮展過程中分子機制及其相關研究有深入了解與認識。積極探尋肺癌預測分子靶向和化療治療療效、預后的分子預測標誌，部分研究成果已應用於臨床實踐。

從事腫瘤臨床工作多年，對胸部腫瘤尤其是肺癌、胸膜間皮瘤、胸腺腫瘤的規範化、個體化、多學科綜合治療具有豐富經驗及深厚的學術造詣，尤其在肺癌基因分型個體化診治方面引領國內走向，擅長將臨床實踐與轉化研究成果有機結合，指導臨床。

國內外腫瘤核心期刊J Clin. Oncol, Cancer Research, Clin Cancer research等雜誌發表論文100餘篇。2008年入選國家“十、百、千”人才計劃。2010年獲得國家自然科學基金“傑出青年基金”資助。獲2011年中國青年女科學家獎及北京市學科帶頭人基金。先後獲得中國抗癌協會科技進步一等獎、北京市科技進步三等獎、中華醫學會醫學獎三等獎、教育部科技成果二等獎、華夏科技成果二等獎等。

兼任中國抗癌協會肺癌專業委員會常務委員，北京醫學會腫瘤專業委員會副主任委員，中國臨床腫瘤協會(CSCO)執行委員，中國抗癌協會小細胞肺癌專家委員會副主任委員，中國抗癌協會肉瘤專家委員會副主任委員；《中華結核與呼吸雜誌》編委、《中國肺癌雜誌》編委、《Clinical Lung cancer》、《Thoracic Oncology》編委。

近期代表性論著(PI或第一作者)

1.Hua Bai, Zhijie Wang, Keneng Chen, Jun Zhao, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang1, Xiaozheng Kang, Jie Wang. Influence of Chemotherapy on EGFR Mutation Status for Patients with Non-small Cell Lung Cancer. J Clin Oncol，2012, 30:3077-83. (PI)

2.Zhijie Wang, Tongtong An, Tony Mok, Jie Wang et al. A retrospective analysis of maintenance versus delayed EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research.2012,24(1):1-12. (PI)

3.Zhijie Wang, Xuchao Zhang, Hua Bai, Jun Zhao, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Shuhang Wang, Yuyan Wang, Yilong Wu and Jie Wang. NSCLC patients with EML4-ALK rearrangement cannot benefit from EGFR-TKI. Oncology, 2012. (PI)

4.Mei na Wu, Jun Zhao, Sonya Wei Song，Hua Bai，Minglei Zhuo ,Shuhang Wang, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Jie Wang. Plasma EGFR mutations are not associated with response to first-line chemotherapy but with prognosis in the Chinese patients with advanced non-small cell lung cancer. lung cancer 2010, 67(3):343-347 (PI)

5.Shuhang wang , Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Meina Wu. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced NSCLC. Clin Cancer Res 2010, 15,16(4):1324-1330 (PI)

6.Hua Bai, Li Mao, Shuhang Wang, Jun Zhao, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan Meina Wu, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Yuye Wang, Jie Wang. EGFR Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. J Clin Oncol , 2009,( 27)：2663-2669 (PI)

7.Xin Wang , Jun Zhao , Lu Yang, Li Mao，Jie Wang.et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol (2010) 27:484–490 (PI)

WANG J. Manisha Bhutani1, Ashutosh K. DNMT3B Variants Regulate DNA Methylation in a Promoter-Specific Manner. Cancer Res 2007,67: 10647-10652

8.Jun Zhao, Zhi-jie Wang, Jian-chun Duan. Jie Wang .et al. A phase II Clinical Trial of Celecoxib Combined with Platinum-based Regimen as First-line Chemotherapy for Advanced Non-small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression. Chin J Cancer Res 2009 21(1):1-12 (PI)

9.Ning-hong Liu, Hua Bai，Lu Yang, ming-lei Zhuo, Shu-hang Wang,Jun Zhao,Jie Wang. Expression of DNMT3B Variants and its association with estrogen/progestogen receptor status in breast cancer. Chin J Cancer Res 2009, 21(3):229-234 (PI)

10.Jianchun Duan, Lu Yang, Jie Wang, Meina Wu, Tongtong An, Jun Zhao. Retrospective analysis of cetuximab combination with chemotherapy in advanced non-small-cell lung cancer. Chin J Cancer Res 2009,21(3): 229-234 (PI)

Wang shuhang, liu ninhong, wang jie,baihua and mao li ,et al. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter specific DNA methylation in non-small cell lung cancer. Chinese Med J 2008;121(17):1712-1721 (PI)

2020年5月，獲得第二屆全國創新爭先獎。